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for the FDA, EMA, Health Canada and Australia the Australian Therapeutic Goods 
Administration. The studies used to make regulatory decisions were then compared 
to the studies used in the reimbursement decisions of France, Scotland, Canada and 
Australia. Results: In all 15 cases reviewed the FDA, EMA and Health Canada used 
at least one of the same studies to come to their decision and in 13 of the cases 
Australia also used that same study. In 14 cases the FDA approved the drug before 
the other regulatory authorities; the longest time before another regulatory agency 
approved a drug was 15 months for rilpivirine. In six cases the FDA commissioned 
studies that other regulatory bodies and reimbursement agencies used later. All 
of the studies were interventional studies. Reimbursement agencies always used 
studies that were previously cited in regulatory documents. These agencies would 
also use studies intended for the regulatory approval of another drug as a source 
for information in a review. ConClusions: Reimbursement agencies and other 
regulatory agencies are influenced by the FDA in the studies they consider, as illus-
trated by at least six cases in which other agencies used studies commissioned by 
the FDA after approval. This influence is easier to see in the last five years, but may 
be older than that due to improvements in published reports.
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objeCtives: General practitioners (GPs) play an essential role in France in the 
prescription and administration of vaccines. Understanding factors that influence 
GPs’ opinions regarding vaccination would help improve vaccination rate in the 
general population. The study objectives were to understand and describe GPs’ 
attitudes, beliefs and behaviours regarding vaccination, to develop a self-report 
tool enabling characterisation of GPs, to assess the prevalence and determinants of 
vaccination behaviours and to identify the modifiable barriers regarding vaccina-
tion. Methods: Focus groups with French GPs (n= 36) were conducted following a 
semi-structured interview guide. Main themes of the guide were identified through 
a literature review. Qualitative analysis enabled development of a conceptual frame-
work based on the theory of planned behaviour (TPB). Items were then generated 
based on GPs’ quotations. Cognitive debriefing interviews with GPs (n= 10) were 
conducted to assess understanding, acceptability and content validity of the tool. 
Research methods and results were approved by a committee involving GPs, vac-
cination and tool development experts. Results: Focus groups revealed that GPs’ 
attitudes, beliefs and behaviours regarding vaccination varied depending on target 
disease and population. GPs were influenced by factors classified in 6 themes: vac-
cine characteristics, disease characteristics, practical aspects, expected benefits, 
personal background and relationship with patients. These qualitative findings 
supported item generation of the tool to capture 39 detailed concepts. The tool was 
developed to be generic for any disease that could be prevented by vaccination. 
Comprehension testing to confirm the relevance and understanding of the tool is 
underway. ConClusions: The tool was developed following rigorous methodology 
based on documented qualitative research. The TPB seems appropriate for organis-
ing qualitative research findings. Characterisation of GPs based on their attitudes, 
beliefs and behaviours regarding vaccination is expected to predict their intention 
to vaccinate and thus enable development of efficient programs promoting vac-
cination. The next step is to perform psychometric validation.
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objeCtives: It is assumed that agencies influence one another but little has 
been written on the extent of this influence. This analysis aims to explore how 
regulatory decisions affect reimbursement decisions within one HIV drug, daru-
navir. Methods: Documents from the FDA, European Public Assessment Report 
(EPAR), Health Canada, and the Australian Register of Therapeutic Goods together 
with the reimbursement decisions from France, Scotland, Canada and Australia were 
analyzed. The clinical trials found in these documents were compared. Results: 
The FDA approved darunavir ethanolate on June 23, 2006 based on the POWER 1, 2 
and 3 clinical trials. After approval, the FDA also required further reports (to be com-
pleted by December 31, 2007) on two Phase III studies, ARTEMIS and TITAN. Health 
Canada approved darunavir on July 28, 2006 and used the POWER studies along 
with the ARTEMIS and TITAN studies in its decision. The EMA approved darunavir 
on December 2, 2007 but gave conditional authorization a year earlier. EPAR also 
used the TITAN and POWER studies to make its decision. The French reimbursement 
agency used the ARTEMIS and TITAN studies in two recommendations. Scotland 
and Canada cited the ARTEMIS study in their recommendations. Australia used the 
POWER and TITAN studies in two recommendations and the ARTEMIS study in its 
one negative recommendation, citing an inappropriate comparator for the popula-
tion under review. ConClusions: Studies that required further review by the FDA 
after approval were key in determining regulatory decisions by Health Canada, 
EMA and Australia. The reimbursement decisions of France, Scotland, Canada and 
Australia also relied on these commissioned studies.
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chronic (e.g., diabetes, hypercholesterolemia, schizophrenia) rather than life-threat-
ening and that treatments, while costly, lead to significant savings in medical ben-
efits and ultimately leave medication decisions to specialists. Payers are cautiously 
examining potential savings and were willing to institute modest management for 
generics (tier 1) while keeping branded FDCs on preferred tier 2 (branded preferred 
copay). Payers were unwilling to institute, high cost-sharing co-insurance, prior 
authorizations, or require failure for members to access branded HIV medications 
presently or in the near future. ConClusions: Payers recognize the complexity 
of treating HIV, the role of adherence, the high cost of failure and the public health 
component of preventing resistance. We found payers to cautiously look at potential 
cost savings in medication management until all FDC components become generic. 
We found no widespread desire to drive generic adoption in HIV treatment, and little 
interest in the “de-simplification” of currently available FDCs.
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objeCtives: Inadequate or partial treatment of Tuberculosis (TB) is a known factor 
that would promote drug resistance, thus increasing the overall cost of TB manage-
ment. The study objectives are to identify the general characteristics of defaulting 
patients and to estimate the cost impact on health authorities as compared to non-
defaulters. Methods: A retrospective case-control study was carried out in public 
treatment centres in Selangor, Malaysia. Defaulter is defined as TB patient who has 
interrupted treatment for two consecutive months or more and did not complete 
their treatment. All subjects were selected from 2011 TB District Registry database. 
Patients’ medical case notes and baseline characteristics were reviewed and analysed. 
The direct costs of TB management were estimated from public health cost refer-
ences. The study was performed from a government’s perspective. Results: A total 
of 176 defaulters and 204 non-defaulters were studied. Foreign-born patients showed 
a higher risk (OR= 5.929; p < 0.01) of defaulting treatment. Unemployed patients were 
also more likely to default treatment (OR= 1.521 p> 0.05). Defaulters were more likely 
to default treatment during intensive phase as compared to maintenance phase 
(68.1% vs. 31.9%; p< 0.05). No other significant findings were observed between the 
two groups including age, ethnicity, severity of x-ray changes, type of TB and overall 
medical risk factors. Mean cost of the non-defaulter group is higher than the defaulter 
group due to a complete treatment (RM 1,259.62 vs. RM 575.58; p< 0.05). No significant 
treatment cost difference was observed in foreign-born defaulters as compared to 
local Malaysians (mean: RM 576.43 vs. RM 573.78; p> 0.05). ConClusions: Data from 
this study suggest TB treatment should be completed to avoid a potential huge waste 
of resources. More attentions are required for foreign-born defaulters due to over-
all consequence in public health and management cost. Additional costs would be 
required if susceptible TB strains of the defaulters turned into more virulent strains.
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objeCtives: To describe the burden of influenza for children and adults diagnosed 
with seasonal influenza in Germany. Methods: The study was based on a retro-
spective database analysis, using a longitudinal electronic medical records database 
(IMS® Disease Analyzer). Patients with influenza episodes (ICD-10 diagnosis J09-
11) being observable 12 months before index date and 1 month afterwards were 
included. The selection window was May 2010 to April 2012 to cover two influenza 
seasons. Results: A total of 23,068 influenza episodes (19,446 patients) managed 
by primary care practitioners (PCP) and 7,295 episodes (5,988 patients) managed by 
pediatricians were eligible. Mean age of patients was 43±20 years in the PCP panel 
and 7±4 years in the pediatrician panel. The presence of clinical risk factors was 
documented for 40% of episodes in adults and 31% of episodes in children. The most 
common risk factors were cardiovascular diseases in adults (28%) and chronic res-
piratory diseases in children (26%). The presence of risk factors correlated with the 
number of episodes/patient. Influenza episodes were frequently accompanied by 
complications (adults: 38%; children: 57%). Bronchitis (adults: 16%, children: 20%) 
and acute upper respiratory infections (adults: 15%, children: 21%) accounted for the 
most frequent complications. Mean number of physician visits was 1.2± 0.5 in adults 
and 1.5±0.8 in children. Nevertheless one in three children (34%) had more than one 
visit/episode due to complications. About 60% of episodes (adults: 60%; children: 64%) 
with at least one complication were reported in patients without risk factors. About 
50% of patients received drug prescriptions related either to influenza diagnosis or 
complications. ConClusions: This study demonstrates that in Germany seasonal 
influenza is associated with a substantial disease burden and considerable resource 
utilization, which can be preventable by vaccination. The findings may suggest the 
modification of the current vaccination recommendation for at risk populations.
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objeCtives: This analysis compares the studies that four regulatory agencies used 
to make their decisions and compares the relationship between the reasons for 
regulatory decisions and reasons for reimbursement decisions. Methods: The 
scientific discussions and the studies used to make regulatory decisions for 15 
different HIV drugs approved over the last 12 years (2000-2012) were compared 
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p3= 0.002). Compared to the preoperatively measured, the fail of the three meas-
ured respiratory functional values on the 7th postoperative day was significantly 
smaller in Group1 than Group2 (VC, FEV1, PEF; Group1: 14.18±12.61%; 12.82±14.31%; 
-6.29±18.46%; Group2: 25.60±16.11%; 23.05±14.93%; 13.70±19.28%; p1= 0.043, p2 = 0.046, 
p3 = 0.004). There was no difference between groups in duration of mechanical ven-
tilation and average stay of intensive care unit. Incidence of atelectasis was 10% in 
Group1, while 0% in Group2. Pre- and postoperative respiratory functional values 
did not correlate significantly with extubation time (p> 0.05). ConClusions: The 
applying of preoperative PT to cardiac surgical patients with COPD is effective since 
the examined respiratory functional values reduced less and increased better in the 
postoperative period at the preoperatively treated group.
Prs3
resPIrAtory syNcytIAl vIrus hosPItAlIzAtIoNs IN the cANAdIAN 
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objeCtives: Paediatric advisory committee guidelines recommend palivizumab 
prophylaxis for infants at high risk for respiratory syncytial virus (RSV) infection. 
The objective of this study is to compare the hospitalization rates for respiratory 
illness (RIH) and RSV-positive hospitalizations (RSVH) among infants who received 
palivizumab for various indications. Methods: The Canadian Registry for Synagis 
(CARESS) is a prospective registry of infants who have received ≥ 1 dose of palivizumab 
per RSV season across Canada. Demographic data were collected in 32 Canadian 
national sites during the 2005-2012 RSV seasons. Respiratory illness related hospi-
talization events were recorded monthly. Standard risk indications that qualified for 
RSV prophylaxis were categorized as prematurity (≤ 35 completed weeks gestational 
age), chronic lung disease or bronchopulmonary dysplasia (CLD), hemodynamically 
significant congenital heart disease (CHD), and other serious underlying medical 
disorders (MD). A Cox proportional hazards analysis was conducted to examine differ-
ences in hospitalization rates between the indications. Results: Of the 13,310 infants 
enrolled, 8751 were premature, 1048 had CLD, 1414 had CHD, and 2097 qualified with 
MDs. The overall RIH rate was 6.6% (n= 875) with premature infants having a signifi-
cantly lower rate than the other groups (4.4% vs. 12.2% [CLD], 10.3% [CHD], 10.3% [MD]; 
B= -0.770, df= 1, p< 0.0005). Details of hospitalizations did not differ between groups, 
except the number that were admitted to the Intensive Care Unit which was signifi-
cantly different between groups (χ 2= 11.420, df= 3, p= 0.010). The overall RSVH rate was 
1.55% but was also significantly lower for prematurity (prematurity, 1.36%; CLD, 1.64%; 
CHD, 2.05%; MD, 2.03%; p< 0.0005), with no significant differences between the groups 
in terms of time to RSV hospitalization (χ 2= 1.833, df= 3, p= 0.608). ConClusions: 
RIH and RSVH rates were dissimilar across the groups with premature infants being 
significantly lower compared to the others. However there were no identified group 
differences regarding time to first RSVH.
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objeCtives: To assess the impact of the front loading phone calls counselling on the 
abstinence prevalence at 3 and 6 months after quit date among smokers in Penang, 
Malaysia. Methods: The study was carried out at Quit Smoking Clinic of two major 
hospitals in the state of Penang, Malaysia. All the eligible tobacco users who attended 
the clinics between February 1 and October 31, 2012 were invited. Participants were 
randomly assigned to receive either the usual care (a combination of nicotine gum 
for the first 2 weeks and cognitive behaviour therapy); (control group), or the previous 
combination plus extra counselling sessions through phone calls during the first month 
of quit attempt (intervention group). Results: Two hundred thirty-one subjects were 
recruited during the period under review. The mean age of starting smoking in the 
study population was 17.38 ± 3.9 years. The vast majority of our cohort (96.1%) was 
male. Participants smoked about 14 cigarettes per day on average (mean = 13.78 ± 7.0). 
At 3 months follow-up point, control group was less likely to quit smoking compared 
to intervention group but this did not reach statistical significance (OR = 0.669; 95% CI 
= 0.395-1.133, P = 0.86). However, at 6 months, the abstinence rate significantly differed 
between the standard care and combination of standard care and extra phone calls after 
verification with exhaled carbon monoxide (48.6% vs. 71.7%, respectively: < 0.001). The 
control group were significantly less likely to quit smoking (OR = 0.375; 95% CI = 0.217-
0.645, P< 0.001). ConClusions: Smoking cessation intervention consisting of phone 
calls delivered counselling during the first month of quit attempt results in significantly 
higher abstinence rates compared with a standard care approach. Therefore, the front 
loading counselling is a promising treatment strategy that should be evaluated further.
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objeCtives: Palivizumab is recommended for respiratory syncytial virus (RSV) 
prophylaxis. CARESS tracks palivizumab use and respiratory outcomes in high-risk 
infants, including those with congenital airway anomalies (CAA). Our objective was 
to compare hazards for hospitalization for respiratory illness (RIH) and RSV (RSVH) 
in CAA infants versus those prophylaxed for: 1) other medical disorders (MD) and 2) 
standard indications (SD). Methods: Infants were prospectively recruited from 32 
Canadian sites who received ≥ 1 dose of palivizumab during the 2005-2012 RSV sea-
objeCtives: Modern medicine provides continuous improvement of diagnosis, treat-
ment and prevention methods in accordance with the requirements of best medical 
practice. The system of medical care standardization with regard of the evidence-
based medicine is focused on developing medical and technological documents that 
assist a doctor to act effectively in specific clinical situations, avoiding inefficient and 
false interventions. In view of this, the Ministry of Health of Ukraine has approved 
the methodology for development of medical and technological documents on the 
basis of evidence. Methods: Evidence of clinical effectiveness is the main crite-
rion in choosing the treatment methods combating tuberculosis. Results: Ukraine 
has recently introduced the methodology of developing unified clinical protocols 
of medical care based on adapted clinical guidelines, which in turn are the result 
of adaptation of the best international practice. In particular, within the project of 
combating TB the adapted clinical guidelines was developed based on the documents 
of NICE and WHO. In developing the protocol there identified found differences in 
the tuberculosis treatment in Ukraine compared to the best practice, which resulted 
in amendments to the corresponding regulations in health care. ConClusions: 
Practical recommendations derived from the evidence-based medicine allowed the 
change of approaches to diagnosis and treatment of tuberculosis in Ukrainian regu-
lations. 3-time examination by sputum smear and culture microscopy is replaced 
by 2-time, the duration of the basic course of chemotherapy is reduced from 8 to 6 
months and its intensity is reduced from 5-component to 4-component treatment for 
the treatment of new and recurrent cases of tuberculosis with sensitive mycobacteria. 
In order to integrate these changes into clinical practice local protocols and critical 
pathways for management of tuberculosis are developing in all health care facilities 
taking into account peculiarities of the region and available resources of the hospitals.
resPIrAtory-relAted dIsorders – clinical outcomes studies
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objeCtives: ICS/LABA fixed combinations are used in patients with COPD with 
a history of repeated exacerbations i.e. worsening of disease including infections 
and who have significant symptoms despite regular bronchodilator therapy. This 
study describes the characteristics of COPD patients initiating ICS/LABA in English 
primary care. Methods: Patients with first prescription (index date) of flutica-
sone/salmeterol (FP/SM) or budesonide/formoterol (BUD/FM) between 01.01.2005-
31.10.2011 and a prior COPD record were selected from CPRD primary care records 
linked to Hospital Episode Statistics. Baseline characteristics prior to first ICS/LABA 
prescription were described as proportions, means and rates (95%CI). Prior exac-
erbations were defined as: antibiotic or oral corticosteroid prescriptions or COPD 
hospitalisation; multiple events within 14 days were treated as one event. Results: 
26,875 patients age≥ 40 at index were included with 75.9% initiating FP/SM and 
24.1% BUD/FM; mean age 70.3(70.1-70.4) and 69.0(68.8-69.3) years, respectively. In 
both cohorts 54% were male, approximately 36% current smokers, and 56% past 
smokers. Pneumonia within 1-year prior to index was slightly higher in FP/SM 
patients (1.9%(1.9-1.9)) compared to 1.4%(1.4-1.4) in BUD/FM), as was prior mean 
annual COPD hospitalisation rate (0.17(95%CI:0.16-0.17); 0.11(95%CI:0.10-0.12)). 
Amongst FP/SM patients 12.7%(95%CI:12.6-12.9) had COPD hospitalisations 1-year 
prior with 9.2%(95%CI:8.9-9.4) amongst BUD/FM. 37.2%(95%CI:36.7-37.7) of FP/SM 
patients received tiotropium 1-year prior with 35.4%(95%CI:34.5-36.2) amongst BUD/
FM. The majority of patients had received short-acting ß2-agonist; FP/SM patients: 
89.8%(95%CI:88.6-91.1), BUD/FM patients: 84.8%(95%CI :82.7-86.8). Proportions 
receiving inhaled-corticosteroids within 1-year prior was 50.9%(95%CI:50.3-51.6) and 
48.0(95%CI:46.8-49.2) for FP/SM and BUD/FM, respectively, oral-steroids figures were 
42.2%(95%CI:41.7-42.8) and 39.8%(95%CI:38.8-40.8), respectively, and mean annual 
exacerbation rate was 2.15(95%CI :2.12-2.18) and 2.02(95%CI:1.96-2.07), respectively, 
with 75.3%(95%CI:74.2-76.3) and 73.9%(95%CI:72.1-75.7), respectively, having exac-
erbations. ConClusions: Both groups had similar burden of COPD disease prior 
to starting fixed combination. The crude prevalences for some baseline character-
istics were slightly higher in FP/SM vs. BUD/FM highlighting the need for rigorous 
propensity score matching in any comparative outcomes research.
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objeCtives: Chronic Obstructive Pulmonary Disease (COPD) associated with heart 
disease is common; this fact leads to increase the number of postoperative compli-
cations. The aim of this study was to evaluate the benefits of preoperative physi-
otherapy (PT) among patients with COPD. Methods: Thirty-seven patients with 
COPD were included in the study those who underwent open heart surgery. Group1 
(n= 17) participated in pre- and postoperative PT while Group2 (n= 20) received only 
postoperative PT. Inclusion criteria: open heart surgery and patients diagnosed 
with COPD or have FEV1< 80%. Spirometric measurements (vital capacity= VC, 
forced expiratory volume= FEV1, maximum expiratory pressure= PEF) performed 
preoperatively and on the 3rd and 7thpostoperative days. Operative data, duration of 
mechanical ventilation, average stay of intensive care unit, incidence of atelectasis 
were also assessed. IBM SPSS Statistics 20 software was used for statistical analysis; 
t-test and Pearson-correlation was applied (p< 0.05). Results: VC, FEV1, PEF showed 
significantly decrease in Group1 (21.29±13.40%; 19.71±17.96%; 4.18±20.09%) com-
pared to Group2 (34.70±17.54%; 32.85±11.95%; 24.65±21.65%), (p1= 0.013, p2= 0.011, 
